{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:08:17Z","timestamp":1784354897943,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1996,7,1]],"date-time":"1996-07-01T00:00:00Z","timestamp":836179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Urology and Nephrology"],"published-print":{"date-parts":[[1996,7]]},"DOI":"10.1007\/bf02550957","type":"journal-article","created":{"date-parts":[[2007,1,5]],"date-time":"2007-01-05T11:29:51Z","timestamp":1167996591000},"page":"499-509","source":"Crossref","is-referenced-by-count":14,"title":["BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: Results of a prospective randomized study using modified treatment schemes"],"prefix":"10.1007","volume":"28","author":[{"given":"M. D.","family":"Melekos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zarakovitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dandinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fokaefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dauaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Barbalias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02550957_CR1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0022-5347(17)43644-5","volume":"138","author":"H. W. Herr","year":"1987","unstructured":"Herr, H. W., Laudone, V. P., Whitmore, W. F. Jr.: An overview of intravesical therapy for superficial bladder tumors.J. Urol., 138, 1363 (1987).","journal-title":"J. Urol."},{"key":"BF02550957_CR2","first-page":"237","volume-title":"BCG in Superficial Bladder Cancer","author":"J. A. Martinez-Pineiro","year":"1989","unstructured":"Martinez-Pineiro, J. A., Jimenez-Leon, J. S., Martinez-Pineiro, L. Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Garcia Matres, M. J., C\u00e1rcamo, P.: Intravesical therapy comparing BCG, adriamycin and thiotepa in 200 patients with superficial bladder cancer: A randomized prospective study. In: F. M. J. Debruyne, L. Denis, A. P. M. van der Meijden (eds): BCG in Superficial Bladder Cancer. Alan R. Liss. Inc., New York 1989, pp. 237\u2013252."},{"key":"BF02550957_CR3","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"D. L. Lamm","year":"1991","unstructured":"Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A. Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. D., Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional cell carcinoma of the bladder.N. Engl. J. Med., 325, 1205 (1991).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BF02550957_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000475201","volume":"27","author":"D. L. Lamm","year":"1995","unstructured":"Lamm, D. L.: BCG in perspective: Advances in the treatment of superficial bladder cancer.Eur. Urol., 27 (Suppl. 1), 2 (1995).","journal-title":"Eur. Urol."},{"key":"BF02550957_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(83)80029-2","volume":"10","author":"F. Ganzina","year":"1993","unstructured":"Ganzina, F.: 4\u2032-epi-doxorubicin, a new analogue of doxorubicin: Preliminary overview of preclinical and clinical data.Cancer Treat. Rev., 10, 1 (1993).","journal-title":"Cancer Treat. Rev."},{"key":"BF02550957_CR6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1986.4.3.425","volume":"4","author":"R. L. Cersonimo","year":"1986","unstructured":"Cersonimo, R. L., Hong, W. K.: Epirubicin: A review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue.J. Clin. Oncol., 4, 425 (1986).","journal-title":"J. Clin. Oncol."},{"key":"BF02550957_CR7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF00256171","volume":"16","author":"Y. Matsumura","year":"1986","unstructured":"Matsumura, Y., Tsushima, T., Ozaki, Y., Yoshimoto, J., Akagi, T., Obama, T. Nasu, Y., Ohmori, H.: Intravesical chemotherapy with 4\u2032-epi-adriamycin in patients with superficial bladder tumors.Cancer Chemother. Pharmacol., 16, 176 (1986).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BF02550957_CR8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0022-5347(17)38152-1","volume":"146","author":"K. H. Kurth","year":"1991","unstructured":"Kurth, K. H., Vijgh, W. J. V., ten Kate, F., Bogdanowitz, J. F., Carpenter, P. J., van Reyswoud, I.: Phase 1\/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder.J. Urol., 146, 1508 (1991).","journal-title":"J. Urol."},{"key":"BF02550957_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000474798","volume":"21","author":"F. Calais da Silva","year":"1992","unstructured":"Calais da Silva, F., Ferrito, F., Brandao, T., 4\u2032-epi-doxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.Eur. Urol., 21, 42 (1992).","journal-title":"Eur. Urol."},{"key":"BF02550957_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-5347(17)37240-3","volume":"147","author":"M. D. Melekos","year":"1992","unstructured":"Melekos, M. D., Dauaher, H., Fokaefs, E., Barbalias, G.: Intravesical instillations of 4\u2032-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: Results of a controlled prospective study.J. Urol., 147, 371 (1992).","journal-title":"J. Urol."},{"key":"BF02550957_CR11","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8","volume":"72","author":"M. D. Melekos","year":"1993","unstructured":"Melekos, M. D., Chionis, H., Paranychianakis, G., Dauaher, H.: Intravesical 4\u2032-epidoxorubicin (epirubicin) versus bacillus Calmette-Gu\u00e9rin: A controlled prospective study on the prophylaxis of superficial bladder cancer.Cancer, 72, 1749 (1993).","journal-title":"Cancer"},{"key":"BF02550957_CR12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"W. Oosterlinck","year":"1993","unstructured":"Oosterlinck, W., Kurth, K. H., Schr\u00f6der, F., Bultinck, J., Hammond, B., Sylvester, R. and the Members of the EORTC Genitourinary Group: A prospective EORTC Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.J. Urol., 149, 749 (1993).","journal-title":"J. Urol."},{"key":"BF02550957_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000227228","volume":"50","author":"M. D. Melekos","year":"1993","unstructured":"Melekos, M. D.: Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule.Oncology, 50, 40 (1993).","journal-title":"Oncology"},{"key":"BF02550957_CR14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0021-9681(58)90126-7","volume":"8","author":"S. J. Cutler","year":"1958","unstructured":"Cutler, S. J., Ederer, F.: Maximum utilization of the life-table method in analyzing survival.J. Chron. Dis., 8, 699 (1958).","journal-title":"J. Chron. Dis."},{"key":"BF02550957_CR15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-5347(17)52205-3","volume":"129","author":"H. Zincke","year":"1983","unstructured":"Zincke, H., Utz, D. C., Taylor, W. F., Myers, R. P., Leary, F. J.: Influence of thiotepa and doxorubicin instillations at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double-blind, controlled trial.J. Urol., 129, 505 (1983).","journal-title":"J. Urol."},{"key":"BF02550957_CR16","first-page":"215","volume-title":"BCG in Superficial Bladder Cancer","author":"M. S. Soloway","year":"1989","unstructured":"Soloway, M. S., Jordan, A. M., Murphy, W. M.: Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. In: F. M. J. Debruyne, L. Denis, A. P. M. van der Meijden (eds): BCG in Superficial Bladder Cancer. Alan R. Liss Inc., New York 1989, pp. 215\u2013236."},{"key":"BF02550957_CR17","first-page":"43","volume-title":"Recent Progress in Bladder and Kidney Cancer","author":"D. L. Lamm","year":"1992","unstructured":"Lamm, D. L., Griffith, J. D.: The place of intravesical chemotherapy as defined by the results of prospective randomized studies (substances and treatment schemes). In: Recent Progress in Bladder and Kidney Cancer. Wiley-Liss Inc., New York 1992, pp. 43\u201353."},{"key":"BF02550957_CR18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-5347(01)67608-0","volume":"153","author":"Ch. Bouffioux","year":"1995","unstructured":"Bouffioux, Ch., Kurth, K. H., Bono, A., Oosterlinck, W., Boecken Kruger, C., de Pauw, M., Sylvester, R. and Members of the EORTC Genitourinary Group. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 EORTC randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment.J. Urol., 153, 934 (1995).","journal-title":"J. Urol."},{"key":"BF02550957_CR19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1464-410X.1978.tb02816.x","volume":"50","author":"B. H. Page","year":"1978","unstructured":"Page, B. H., Levison, V. B., Curwen, M. P.: The site of recurrence of noninfiltrating bladder tumors.Br. J. Urol., 50, 237 (1978).","journal-title":"Br. J. Urol."},{"key":"BF02550957_CR20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"R. A. Badalament","year":"1987","unstructured":"Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F. Jr., Fair, W. R., Oettgen, H. F.: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer.J. Clin. Oncol., 5, 441 (1987).","journal-title":"J. Clin. Oncol."},{"key":"BF02550957_CR21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","volume":"138","author":"M. A. Hudson","year":"1987","unstructured":"Hudson, M. A., Ratliff, T. L., Gillen, D. P., Haaff, E. O., Dresner, S. M., Catalona, W. J.: Single course versus maintenance bacillus Calmette-Gu\u00e9rin therapy for superficial bladder tumors: A prospective randomized trial.J. Urol., 138, 295 (1987).","journal-title":"J. Urol."},{"key":"BF02550957_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"W. J. Catalona","year":"1987","unstructured":"Catalona, W. J., Hudson, M. A., Gillen, D. P., Andriole, G. L., Ratliff, T. L.: Risks and benefits of repeated course of intravesical bacillus Calmette-Gu\u00e9rin therapy for superficial bladder cancer.J. Urol., 137, 220 (1987).","journal-title":"J. Urol."},{"key":"BF02550957_CR23","first-page":"230","volume":"144","author":"T. L. Ratliff","year":"1989","unstructured":"Ratliff, T. L., Catalona, W. J.: Depressed proliferative responses in patients treated with 12 weeks of intravesical BCG.J. Urol., 144, 230 A (Abstract 144), Part 2 (1989).","journal-title":"J. Urol."},{"key":"BF02550957_CR24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)49690-X","volume":"132","author":"A. Morales","year":"1984","unstructured":"Morales, A.: Long-term results and complications of intracavitary BCG therapy for bladder cancer.J. Urol., 132, 457 (1984).","journal-title":"J. Urol."},{"key":"BF02550957_CR25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","volume":"6","author":"H. W. Herr","year":"1988","unstructured":"Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. L., Freedman, B. D., Melamed, M. R., Whitmore, W. F. Jr.: BCG therapy alters the progression of superficial bladder cancer.J. Clin. Oncol., 6, 1450 (1988).","journal-title":"J. Clin. Oncol."},{"key":"BF02550957_CR26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0022-5347(17)39546-0","volume":"144","author":"D. E. Coplen","year":"1990","unstructured":"Coplen, D. E., Marcus, M. D., Myers, J. A., Ratliff, T L., Catalona, W. J.: Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Gu\u00e9rin: Analysis of possible predictions of response free of tumor.J. Urol., 144, 652 (1990).","journal-title":"J. Urol."},{"key":"BF02550957_CR27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02549774","volume":"22","author":"M. D. Melekos","year":"1990","unstructured":"Melekos, M. D., Pantazakos, A., Markou, S., Skopa, C., Athanassopoulos, A., Barbalias, G.: Intravesical bacillus Calmette-Gu\u00e9rin administration in the prophylaxis of superficial bladder cancer.Int. Urol. Nephrol., 22, 433 (1990).","journal-title":"Int. Urol. Nephrol."},{"key":"BF02550957_CR28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000281695","volume":"45","author":"M. D. Melekos","year":"1990","unstructured":"Melekos, M. D.: Intravesical bacillus Calmette-Gu\u00e9rin prophylactic treatment for superficial bladder tumors: Results of a controlled prospective study.Urol. Int., 45, 137 (1990).","journal-title":"Urol. Int."},{"key":"BF02550957_CR29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0094-0143(21)00422-5","volume":"19","author":"S. A. Brosman","year":"1992","unstructured":"Brosman, S. A.: Bacillus Calmette-Gu\u00e9rin immunotherapy.Urol. Clin. N. Amer., 19, 557 (1992).","journal-title":"Urol. Clin. N. Amer."},{"key":"BF02550957_CR30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","volume":"149","author":"M. D. Melekos","year":"1993","unstructured":"Melekos, M. D., Chionis, H., Pantazakos, A., Fokaefs, E., Paranychianakis, G., Dauaher, H.: Intravesical bacillus Calmette-Gu\u00e9rin immunoprophylaxis of superficial bladder cancer: Results of a controlled prospective trial with a modified treatment schedule.J. Urol., 149, 744 (1993).","journal-title":"J. Urol."},{"key":"BF02550957_CR31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","volume":"152","author":"R. B. Nadler","year":"1994","unstructured":"Nadler, R. B., Catalona, W. J., Hudsoin, M. A., Ratliff, T. L.: Durability of the tumor-free response for intravesical bacillus Calmette-Gu\u00e9rin therapy.J. Urol., 152 367 (1994).","journal-title":"J. Urol."},{"key":"BF02550957_CR32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-5347(17)44277-7","volume":"137","author":"M. S. Soloway","year":"1987","unstructured":"Soloway, M. S., Perry, A.: Bacillus Calmette-Gu\u00e9rin for the treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and\/or mitomycin C.J. Urol., 137, 871 (1987).","journal-title":"J. Urol."},{"key":"BF02550957_CR33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","volume":"141","author":"H. W. Herr","year":"1989","unstructured":"Herr, H. W., Badalament, R. A., Amato, D. A., Laudone, V. P., Fair, W. R., Whitmore, W. F. Jr.: Superficial bladder cancer treated with bacillus Calmette-Gu\u00e9rin: A multivariable analysis of factors affecting tumor progression.J. Urol., 141, 22 (1989).","journal-title":"J. Urol."},{"key":"BF02550957_CR34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","volume":"146","author":"F. Pagano","year":"1991","unstructured":"Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D., Garbeghlio, A.: A low dose bacillus Calmette-Gu\u00e9rin regimen in superficial bladder cancer therapy: Is it effective?.J. Urol., 146, 32 (1991).","journal-title":"J. Urol."}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02550957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02550957\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02550957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T09:10:57Z","timestamp":1628327457000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02550957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,7]]}},"alternative-id":["BF02550957"],"URL":"https:\/\/doi.org\/10.1007\/bf02550957","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,7]]}}}